WEBINAR Is the new Congress ready to lower drug costs? With STAT’s Washington Correspondents, Lev Facher and Nicholas Florko Agenda
1. The Midterms 2. The Trump Administration 3. Legislation to Watch 4. Investigations 5. Lobbying The Midterms GOP holds Senate, Dems gain 40 House seats
Senate Majority Leader Mitch McConnell (R-Ky.) Speaker of the House Nancy Pelosi (D-Calif.)
Slide 4 The House Ways & Means Committee
Rep. Richard Neal (D-Mass.) Rep. Lloyd Doggett (D-Texas)
Slide 5 The House Energy & Commerce Committee
Rep. Anna Eshoo (D-Calif.) Rep. Frank Pallone (D-N.J.)
Slide 6 The House Energy & Commerce Committee
“We are going to do at least one diabetes hearing.”
Rep. Diana DeGette (D-Colo.) Slide 7 The House Oversight Committee
House Freedom Caucus House Progressive Caucus
Jim Jordan Elijah Cummings Mark Meadows Carolyn Maloney Justin Amash Lacy Clay Paul Gosar Jamie Raskin Jody Hice Katie Hill Michael Cloud Peter Welch Ralph Norman Mark DeSaulnier Chip Roy Brenda Lawrence Mark Green Ro Khanna Jimmy Gomez Alexandria Ocasio-Cortez Ayanna Pressley Rashida Tlaib
Slide 8 Senate Finance Committee
Sen. Chuck Grassley (R-Iowa) Sen. Ron Wyden (D-Ore.)
Slide 9 Bipartisan Collaboration on SFC
“This legislation is a significant step forward to fixing the problems in our health care system that have allowed pharmaceutical manufacturers to price gouge taxpayers and consumers for too long.”
—Sen. Grassley on the Right Rebate Act of 2018, co-sponsored with Wyden
Slide 10 The Senate HELP Committee
Sen. Lamar Alexander (R-Tenn.) Sen. Mitt Romney (R-Utah)
Slide 11 The Senate Judiciary Committee
Sen. Lindsey Graham (R-S.C.)
Slide 12 The Trump Administration The White House
Joe Grogan, Chair, Domestic Policy Council Shahira Knight, White House Director of Former Head of Federal Affairs, Gilead Legislative Affairs
Slide 14 Dept. of Health and Human Services
Alex Azar, HHS Secretary John O’Brien, Senior Advisor to the Secretary for Former President, Lilly USA Drug Pricing Reform
Slide 15 Legislation to Watch Legislation that will be taken seriously
→ Reforms for Medicare Part D → CREATES Act → Preserve Access to Affordable Generics Act (Pay for Delay)
Slide 17 Messaging from 2020 candidates
→ Bernie Sanders’ international price index → Elizabeth Warren’s generic drug manufacturing bill → Klobuchar & Harris’ bill to block price increases → Various iterations of Medicare negotiation → Klobuchar, Brown & Harris’ drug exclusivity bill
Slide 18 Wild cards
→ Grassley-Klobuchar personal drug importation → PBM transparency bills → Cassidy-Warner value-based pricing bill → Wyden’s bill requiring justification for price spikes → Wyden-Grassley bill on Medicaid rebates
Slide 19 Investigations Senate Finance AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck House Oversight & Co., Pfizer, Sanofi, Eli Lilly, AstraZeneca, Teva, Novo Nordisk Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Amgen, Pfizer, Novo Members & Nordisk, Sanofi, AbbVie Companies Impacted
House Energy & Commerce Sanofi, Eli Lilly, Novo Nordisk
Slide 21 Source: Giphy Lobbying Annual Lobbying by PhRMA
$30M
$24M
$18M
TOTAL $12M
$6M
$0M ‘98 ‘99 ‘00 ‘01 ‘02 ‘03 ‘04 ‘05 ‘06 ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 ‘13 ‘14 ‘15 ‘16 ‘17 ‘18
YEAR
Slide 24 Other groups to watch
Slide 25 Q&A Thanks! @levfacher @NicholasFlorko